Regeneron Pharmaceuticals, Inc.
REGN
$689.50
-$28.66-3.99%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.04% | 11.85% | 11.45% | -0.59% | -1.97% |
| Total Other Revenue | -15.58% | -17.43% | 50.79% | 0.78% | 66.41% |
| Total Revenue | 10.33% | 10.65% | 12.32% | -0.54% | 0.58% |
| Cost of Revenue | 16.72% | 16.60% | 17.24% | 7.92% | 6.98% |
| Gross Profit | 4.11% | 5.79% | 11.36% | -8.77% | -4.95% |
| SG&A Expenses | 7.39% | 11.54% | 16.38% | 14.62% | 11.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 2,533.33% | 3,160.00% | 92.42% |
| Total Operating Expenses | 13.91% | 15.12% | 14.57% | 10.52% | 8.66% |
| Operating Income | 1.66% | 2.70% | 7.58% | -24.36% | -14.78% |
| Income Before Tax | -16.51% | 34.41% | 50.35% | -18.33% | -13.37% |
| Income Tax Expenses | 436.67% | 47.96% | 71.00% | -152.99% | -109.40% |
| Earnings from Continuing Operations | -20.86% | 33.02% | 47.90% | -11.71% | -3.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.86% | 33.02% | 47.90% | -11.71% | -3.13% |
| EBIT | 1.66% | 2.70% | 7.58% | -24.36% | -14.78% |
| EBITDA | 2.69% | 3.72% | 8.45% | -20.84% | -12.61% |
| EPS Basic | -21.60% | 30.81% | 46.40% | -12.29% | -2.77% |
| Normalized Basic EPS | 6.24% | 4.40% | 11.93% | -15.34% | -11.79% |
| EPS Diluted | -20.81% | 29.81% | 46.00% | -12.55% | -2.87% |
| Normalized Diluted EPS | 7.24% | 3.61% | 11.61% | -15.60% | -11.97% |
| Average Basic Shares Outstanding | 0.94% | 1.69% | 1.03% | 0.65% | -0.37% |
| Average Diluted Shares Outstanding | 0.00% | 2.47% | 1.32% | 0.96% | -0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
